Table 3.

SPID₄₈ values (LS mean and SE) and effect sizes (95% CI) for the two doses of meloxicam IV, by analysis method

Analysis method	Meloxicam IV 30 mg (n=20)	Meloxicam IV 60 mg (n=20)	Placebo (n=19)
SPID48 values (LS mean ± SE)
W2LOCF	−9241.90 (1411.74)*	−8350.60 (1413.30)*	−1991.30 (1448.20)
LOCF	−1021.90 (1116.74)*	−773.86 (1117.97)*	3668.13 (1145.58)
Effect sizes for the meloxicam IV doses (95% CI)
W2LOCF	1.15 (0.51, 1.79)*	1.01 (0.36, 1.65)*	NA
LOCF	0.94 (0.30, 1.58)*	0.89 (0.25, 1.53)*	NA

Note:

^*P≤0.01 versus placebo.

Abbreviations: IV, intravenous; LOCF, last observation carried forward; LS, least-squares; NA, not applicable; SE, standard error; SPID₄₈, summed pain intensity differences over the first 48 hours; W2LOCF, 2-hour windowed last observation carried forward.